Name: 글로벌 시장 동향
SKU: CD803
Availability: InStock

보고서 요약(국문)

배란 장애 진단 시장 규모
전 세계 배란 장애 진단 시장은 2023년 5억 2,260만 달러에 달했으며, 2024년부터 2031년까지 연평균 5.0%의 성장률을 보이며 2031년에는 7억 6,899만 달러에 이를 것으로 예상됩니다.
배란 장애는 여성 불임의 주요 원인입니다. 배란 장애는 여성의 월경 주기 동안 난자 생성에 이상이 생긴 것을 말합니다. 이러한 장애는 시상하부 기능 장애, 조기 난소 부전, 다낭성 난소 증후군 등으로 인해 발생하는 경우가 많습니다.

배란 장애 진단 시장 동향
배란 장애 진단 시장은 계획 임신 증가, 출산율 감소, 그리고 대중의 다양한 배란 장애에 대한 인식 제고에 힘입어 성장하고 있습니다.
제2형 당뇨병 환자에서 다낭성 난소 증후군(PCOS)의 유병률 증가가 시장 성장을 견인할 것으로 예상됩니다.
다낭성 난소 증후군(PCOS)은 심혈관, 대사 및 심리적 요인과 관련된 흔한 대사 및 내분비 생식 질환으로, 전 세계 여성의 약 7%에 영향을 미칩니다. 2022년 8월 Frontiers in Endocrinology에 발표된 논문에 따르면, 당뇨병(DM)은 전 세계적인 공중 보건 문제입니다. 2021년 전 세계적으로 약 5억 3,700만 명의 성인(20~79세)이 당뇨병 진단을 받았으며, 대부분 젊은 연령층에서 발생합니다. 최근에는 더 젊은 나이에 제2형 당뇨병(T2DM)이 발병하는 환자가 증가하고 있으며, 특히 여성은 가임기에 더 많은 영향을 받습니다. 제2형 당뇨병(T2DM) 여성 환자의 생식 기능 장애가 점차 증가하고 있습니다. T2DM이 없는 환자와 비교했을 때, T2DM 환자는 월경 장애 및 다낭성 난소 증후군(PCOS)과 같은 임상적 변화를 더 많이 나타냅니다. 이는 황체 형성 호르몬(LH)과 인슐린의 작용으로 유발되는 세포 내 안드로겐 수치 상승과 관련이 있을 수 있습니다.
또한, PCOS는 제2형 당뇨병의 내인성 인슐린 저항성과 고인슐린혈증으로 인해 난소 과립 세포가 자극되어 작은 난포의 성장과 수를 증가시키는 질환입니다. PCOS와 T2DM은 생화학적, 임상적, 대사적 특성을 공유하며, 두 질환이 중복되는 경우가 많습니다. PCOS에 T2DM이 동반될 경우 생식계에 심각한 손상을 초래할 수 있습니다. PCOS 환자 수의 증가는 시장 성장을 견인할 것으로 예상됩니다.
그러나 대중의 인식 부족은 시장 성장을 저해할 수 있습니다.
한편, 의료 전문가와 환자 간의 지식 격차는 진단 지연 및 치료의 차이로 이어질 수 있습니다. 게다가, 영향을 받는 여성들에게 근거 기반의 접근 가능한 정보가 부족하여 불만이 커지고 있습니다. 많은 여성들이 배란 장애 진단 정보와 불임의 원인, 그리고 다양한 건강 위험과의 연관성에 대해 알지 못합니다.
COVID-19 영향 분석
COVID-19의 발생은 전 세계 배란 장애 진단 시장에 상당한 영향을 미쳤습니다. 2020년 7월 BMC Medicine에 발표된 논문에 따르면, 가임기 여성에게 가장 흔한 내분비 질환은 다낭성 난소 증후군(PCOS)으로, 유병률이 10~15%에 달하거나 그 이상일 수 있습니다. 이러한 상황에서 COVID-19 감염 위험이 높아졌습니다. 또한, 많은 환자들이 교통 제한과 봉쇄 조치로 인해 팬데믹 기간 동안 정기적인 치료를 받는 데 어려움을 겪었습니다. 팬데믹으로 인해 많은 산업이 문을 닫으면서 시장에 부정적인 영향을 미쳤습니다.

하지만 2021년이 아닌 2022년 중반부터 상황이 개선되면서 환자들은 병원에서 치료를 받을 수 있게 되었습니다. 시장은 예측 기간 동안에도 양호한 성장세를 보일 것으로 예상됩니다.
배란 장애 진단 시장 부문 분석
다낭성 난소 증후군(PCOS) 부문은 예측 기간(2024-2031년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
다낭성 난소 증후군 부문은 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 어떤 경우에는 여성이 배란에 필요한 호르몬을 충분히 생성하지 못합니다. 배란이 일어나지 않으면 난소에 여러 개의 작은 낭종이 생깁니다. 이 낭종은 안드로겐이라는 호르몬을 생성합니다. PCOS를 가진 여성은 종종 안드로겐 수치가 높습니다. 이는 여성의 생리 주기에 더 많은 문제를 일으키고 PCOS의 여러 증상을 유발할 수 있습니다. 생리 주기가 불규칙하고 혈액 검사에서 안드로겐 수치가 높게 나타나는 여성은 PCOS일 가능성이 높습니다. 클리블랜드 클리닉에 따르면 PCOS는 매우 흔하며, 가임기 여성의 최대 15%가 PCOS를 앓고 있습니다. 다낭성 난소 증후군(PCOS)을 진단 및 치료받지 않은 여성은 비만, 고혈압, 임신성 당뇨병, 고콜레스테롤혈증 등 심혈관 질환 위험을 높이는 질환에 걸릴 위험이 있습니다. 따라서 PCOS 진단은 중요하며, PCOS 환자 수 증가로 진단 시장 수요도 증가하고 있습니다. 다낭성 난소 증후군(PCOS)을 특이적으로 진단하는 단일 검사는 없습니다. 의료 전문가들은 골반 검사, 혈액 검사, 초음파 검사를 권장합니다.
배란 장애 진단 시장 지역별 점유율
북미 지역은 전 세계 배란 장애 진단 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 배란 장애 진단 시장을 주도하고 있으며, 예측 기간(2024~2031년) 동안에도 이러한 추세가 지속될 것으로 예상됩니다. 이는 선진적인 의료 인프라와 배란 장애 진단에 대한 대중의 인식이 높아짐에 따라 예측 기간 동안 상당한 시장 규모를 유지할 것으로 전망됩니다. 미국 질병통제예방센터(CDC)에 따르면, 다낭성 난소 증후군(PCOS)은 여성 불임의 가장 흔한 원인 중 하나로, 미국 가임기 여성의 6~12%(최대 500만 명)에 영향을 미칩니다. PCOS 발병률 증가와 여성 건강에 대한 인식 제고가 북미 지역 시장 성장을 견인하고 있습니다. 또한, 주요 기업들은 인수합병 및 신제품 출시와 같은 시장 전략을 적극적으로 추진하고 있습니다. 예를 들어, 2021년 12월 Labcorp는 최고 수준의 비임상 시험 서비스를 제공하는 임상시험수탁기관(CRO)인 Toxikon Corporation을 인수했습니다. Toxikon을 Labcorp Drug Development에 편입함으로써 Labcorp의 강력한 비임상 개발 포트폴리오가 더욱 강화되었습니다.
배란 장애 진단 시장 기업 및 경쟁 환경
배란 장애 진단 시장은 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 시장 성장에 기여하는 주요 기업으로는 Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, Esaote 등이 있습니다. 주요 기업들은 새로운 치료법 출시, 인수, 협력 등 다양한 성장 전략을 채택하고 있으며, 이는 전 세계 배란 장애 진단 시장의 성장에 기여하고 있습니다.

예를 들어,
2022년 7월 Canon Medical Systems USA Inc.는 미네소타주 미니애폴리스에 본사를 둔 의료 영상 장비 유통 및 서비스 제공업체인 NXC Imaging을 인수했습니다.
Toshiba Medical Systems Corporation (TMSC)
개요:
TMSC는 진단용 X선 시스템, 의료용 X선 CT 시스템, 자기공명영상(MRI) 시스템, 컴퓨터 단층촬영(CT) 진단용 초음파 시스템, 방사선 치료 시스템 등을 포함한 의료 장비를 제조, 판매 및 기술 서비스를 제공하는 회사입니다.

치료 유형 포트폴리오:
컴퓨터 단층 촬영(CT): 이 시스템은 기존의 형태학적 진단 외에도 기능적 진단 및 동적 관찰과 같은 새로운 임상적 가치를 제공합니다. 또한 0.35초의 짧은 회전 시간으로 160mm 폭의 3D 이미징을 제공할 수 있으며, 환자 친화적인 의료 서비스로 스캔 시간과 방사선 노출량을 줄여줍니다.
글로벌 배란 장애 진단 시장 보고서는 약 65개 이상의 시장 데이터 표, 65개 이상의 그림, 그리고 200페이지(약) 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Ovulation Disorder Diagnosis Market Size
The Global Ovulation Disorder Diagnosis Market reached US$ 522.60 million in 2023 and is expected to reach US$ 768.99 million by 2031, growing at a CAGR of 5.0% during the forecast period 2024-2031.
Ovulation disorders are the main source of infertility in women or girls. Ovulation disorders are disturbances in the production of an egg during a woman’s menstrual cycle. The disorders often occur due to hypothalamic dysfunction, premature ovarian failure and polycystic ovary syndrome.
Ovulation Disorder Diagnosis Market Dynamics
The ovulation disorder diagnosis market growth is driven by the rising adoption of planned pregnancies, a decrease in fertility rate along with increasing awareness of different ovulation disorders among the public
The prevalence of polycystic ovary syndrome (PCOS) in patients with type 2 diabetes is expected to drive the market growth
Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around 7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.
In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.
The lack of awareness in public will hamper the growth of the market
However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.
COVID-19 Impact Analysis
The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10–15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.
However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.
Ovulation Disorder Diagnosis Market Segment Analysis
The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.
Ovulation Disorder Diagnosis Market Geographical Share
North America region holds the largest market share of the global ovulation disorder diagnosis market
North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2024-2031) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio.
Ovulation Disorder Diagnosis Market Companies and Competitive Landscape
The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.
For instance,
In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.
Toshiba Medical Systems Corporation (TMSC)
Overview:
TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.
Treatment type Portfolio:
Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.
The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

상세 목차

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet By Ovulation Disorders
3.2. Market Snippet By Diagnosis
3.3. Market Snippet By End-users
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising obesity rates
4.1.1.2. The increasing prevalence of diabetes
4.1.2. Restraints:
4.1.2.1. Lack of awareness of diagnosis
4.1.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Ovulation Disorders
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
7.1.2. Market Attractiveness Index, By Ovulation Disorders
7.2. Polycystic Ovarian Syndrome*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Hyperprolactinemia
7.4. Luteal Phase Defect
7.5. Hypothalamus Dysfunction
7.6. Tumors
7.7. Autoimmune Oophoritis
7.8. Primary Ovarian Failure
7.9. Resistant Ovary Syndrome
7.10. Others
8. By Diagnosis
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
8.1.2. Market Attractiveness Index, By Diagnosis
8.2. Laboratory Testing of Hormones*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus
8.4. Ovarian Biopsy
8.5. Others
9. By End-users
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
9.1.2. Market Attractiveness Index, By End-users
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Gynecological Clinics
9.4. Diagnostic Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
10.4.6.
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Treatment type Benchmarking
12. Company Profiles
12.1. Siemens Healthcare*
12.1.1. Company Overview
12.1.2. Treatment type Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. GE Healthcare
12.3. Fujifilm Holdings
12.4. Swiss Precision Diagnostics
12.5. Toshiba Medical Systems Corporation
12.6. Carestream Health
12.7. Genova Diagnostics
12.8. Quest Diagnostics
12.9. LabCorp
12.10. Esaote(*LIST NOT EXHAUSTIVE)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

언급된 주요 기업들

Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp

표 목록 (Tables)

List of Tables

Table 01 Global Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2021, 2025 & 2029 ($ Million)

Table 02 Global Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2021, 2025 & 2029 ($ Million)

Table 03 Global Ovulation Disorder Diagnosis Market Value, By End-users, 2021, 2025 & 2029 ($ Million)

Table 04 Global Ovulation Disorder Diagnosis Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 05 Global Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2021, 2025 & 2029 ($ Million)

Table 06 Global Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2020-2029 ($ Million)

Table 07 Global Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2021, 2025 & 2029 ($ Million)

Table 08 Global Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2020-2029 ($ Million)

Table 09 Global Ovulation Disorder Diagnosis Market Value, By End-users, 2021, 2025 & 2029 ($ Million)

Table 10 Global Ovulation Disorder Diagnosis Market Value, By End-users, 2020-2029 ($ Million)

Table 11 Global Ovulation Disorder Diagnosis Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 12 Global Ovulation Disorder Diagnosis Market Value, By Region, 2020-2029 ($ Million)

Table 13 North America Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2020-2029 ($ Million)

Table 14 North America Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2020-2029 ($ Million)

Table 15 North America Ovulation Disorder Diagnosis Market Value, By End-users, 2020-2029 ($ Million)

Table 16 North America Ovulation Disorder Diagnosis Market Value, By Country, 2020-2029 ($ Million)

Table 17 South America Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2020-2029 ($ Million)

Table 18 South America Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2020-2029 ($ Million)

Table 19 South America Ovulation Disorder Diagnosis Market Value, By End-users, 2020-2029 ($ Million)

Table 20 South America Ovulation Disorder Diagnosis Market Value, By Country, 2020-2029 ($ Million)

Table 21 Europe Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2020-2029 ($ Million)

Table 22 Europe Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2020-2029 ($ Million)

Table 23 Europe Ovulation Disorder Diagnosis Market Value, By End-users, 2020-2029 ($ Million)

Table 24 Europe Ovulation Disorder Diagnosis Market Value, By Country, 2020-2029 ($ Million)

Table 25 Asia-Pacific Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2020-2029 ($ Million)

Table 26 Asia-Pacific Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2020-2029 ($ Million)

Table 27 Asia-Pacific Ovulation Disorder Diagnosis Market Value, By End-users, 2020-2029 ($ Million)

Table 28 Asia-Pacific Ovulation Disorder Diagnosis Market Value, By Country, 2020-2029 ($ Million)

Table 29 Middle East & Africa Ovulation Disorder Diagnosis Market Value, By Ovulation Disorders, 2020-2029 ($ Million)

Table 30 Middle East & Africa Ovulation Disorder Diagnosis Market Value, By Diagnosis, 2020-2029 ($ Million)

Table 31 Middle East & Africa Ovulation Disorder Diagnosis Market Value, By End-users, 2020-2029 ($ Million)

Table 32 Siemens Healthcare: Overview

Table 33 Siemens Healthcare: Product Portfolio

Table 34 Siemens Healthcare: Key Developments

Table 35 GE Healthcare: Overview

Table 36 GE Healthcare: Product Portfolio

Table 37 GE Healthcare: Key Developments

Table 38 Fujifilm Holdings: Overview

Table 39 Fujifilm Holdings: Product Portfolio

Table 40 Fujifilm Holdings: Key Developments

Table 41 Swiss Precision Diagnostics: Overview

Table 42 Swiss Precision Diagnostics: Product Portfolio

Table 43 Swiss Precision Diagnostics: Key Developments

Table 44 Toshiba Medical Systems Corporation: Overview

Table 45 Toshiba Medical Systems Corporation: Product Portfolio

Table 46 Toshiba Medical Systems Corporation: Key Developments

Table 47 Carestream Health: Overview

Table 48 Carestream Health: Product Portfolio

Table 49 Carestream Health: Key Developments

Table 50 Genova Diagnostics: Overview

Table 51 Genova Diagnostics: Product Portfolio

Table 52 Genova Diagnostics: Key Developments

Table 53 Quest Diagnostics: Overview

Table 54 Quest Diagnostics: Product Portfolio

Table 55 Quest Diagnostics: Key Developments

Table 56 LabCorp: Overview

Table 57 LabCorp: Product Portfolio

Table 58 LabCorp: Key Developments

Table 59 Esaote: Overview

Table 60 Esaote: Product Portfolio

Table 61 Esaote: Key Developments

그림 목록 (Figures)

List of Figures

Figure 01 Global Ovulation Disorder Diagnosis Market Share, By Ovulation Disorders, 2020 & 2029 (%)

Figure 02 Global Ovulation Disorder Diagnosis Market Share, By Diagnosis, 2020 & 2029 (%)

Figure 03 Global Ovulation Disorder Diagnosis Market Share, By End-users, 2020 & 2029 (%)

Figure 04 Global Ovulation Disorder Diagnosis Market Share, By Region, 2020 & 2029 (%)

Figure 05 Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 06 Global Ovulation Disorder Diagnosis Market Y-o-Y Growth, By Ovulation Disorders, 2020-2029 (%)

Figure 07 Polycystic Ovarian Syndrome: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 08 Hyperprolactinemia: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 09 Luteal Phase Defect: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 10 Hypothalamus Dysfunction: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 11 Tumors: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 12 Autoimmune Oophoritis: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 13 Primary Ovarian Failure: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 14 Resistant Ovary Syndrome: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 15 Global Ovulation Disorder Diagnosis Market Y-o-Y Growth, By Diagnosis, 2020-2029 (%)

Figure 16 Laboratory Testing of Hormones: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 17 CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 18 Ovarian Biopsy: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 19 Others: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 20 Global Ovulation Disorder Diagnosis Market Y-o-Y Growth, By End-users, 2020-2029 (%)

Figure 21 Hospitals: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 22 Gynecological Clinics: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 23 Diagnostic Centers: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 24 Others: Global Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 25 Global Ovulation Disorder Diagnosis Market Y-o-Y Growth, By Region, 2020-2029 (%)

Figure 26 North America Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 27 North America Ovulation Disorder Diagnosis Market Share, By Ovulation Disorders, 2020 & 2029 (%)

Figure 28 North America Ovulation Disorder Diagnosis Market Share, By Diagnosis, 2020 & 2029 (%)

Figure 29 North America Ovulation Disorder Diagnosis Market Share, By End-users, 2020 & 2029 (%)

Figure 30 North America Ovulation Disorder Diagnosis Market Share, By Country, 2020 & 2029 (%)

Figure 31 South America Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 32 South America Ovulation Disorder Diagnosis Market Share, By Ovulation Disorders, 2020 & 2029 (%)

Figure 33 South America Ovulation Disorder Diagnosis Market Share, By Diagnosis, 2020 & 2029 (%)

Figure 34 South America Ovulation Disorder Diagnosis Market Share, By End-users, 2020 & 2029 (%)

Figure 35 South America Ovulation Disorder Diagnosis Market Share, By Country, 2020 & 2029 (%)

Figure 36 Europe Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 37 Europe Ovulation Disorder Diagnosis Market Share, By Ovulation Disorders, 2020 & 2029 (%)

Figure 38 Europe Ovulation Disorder Diagnosis Market Share, By Diagnosis, 2020 & 2029 (%)

Figure 39 Europe Ovulation Disorder Diagnosis Market Share, By End-users, 2020 & 2029 (%)

Figure 40 Europe Ovulation Disorder Diagnosis Market Share, By Country, 2020 & 2029 (%)

Figure 41 Asia-Pacific Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 42 Asia-Pacific Ovulation Disorder Diagnosis Market Share, By Ovulation Disorders, 2020 & 2029 (%)

Figure 43 Asia-Pacific Ovulation Disorder Diagnosis Market Share, By Diagnosis, 2020 & 2029 (%)

Figure 44 Asia-Pacific Ovulation Disorder Diagnosis Market Share, By End-users, 2020 & 2029 (%)

Figure 45 Asia-Pacific Ovulation Disorder Diagnosis Market Share, By Country, 2020 & 2029 (%)

Figure 46 Middle East & Africa Ovulation Disorder Diagnosis Market Value, 2020-2029 ($ Million)

Figure 47 Middle East & Africa Ovulation Disorder Diagnosis Market Share, By Ovulation Disorders, 2020 & 2029 (%)

Figure 48 Middle East & Africa Ovulation Disorder Diagnosis Market Share, By Diagnosis, 2020 & 2029 (%)

Figure 49 Middle East & Africa Ovulation Disorder Diagnosis Market Share, By End-users, 2020 & 2029 (%)

Figure 50 Siemens Healthcare: Financials

Figure 51 GE Healthcare: Financials

Figure 52 Fujifilm Holdings: Financials

Figure 53 Swiss Precision Diagnostics: Financials

Figure 54 Toshiba Medical Systems Corporation: Financials

Figure 55 Carestream Health: Financials

Figure 56 Genova Diagnostics: Financials

Figure 57 Quest Diagnostics: Financials

Figure 58 LabCorp: Financials

Figure 59 Esaote: Financials

세계 배란 장애 진단 시장 – 2024-2031년

Global Ovulation Disorder Diagnosis Market - 2024-2031